Clinical Trials Logo

Pancreatic Cancer Metastatic clinical trials

View clinical trials related to Pancreatic Cancer Metastatic.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04721301 Completed - Clinical trials for Colorectal Cancer Metastatic

Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

Start date: January 15, 2017
Phase: Phase 1
Study type: Interventional

The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents.

NCT ID: NCT03504423 Completed - Clinical trials for Pancreatic Cancer Metastatic

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Start date: November 9, 2018
Phase: Phase 3
Study type: Interventional

A prospective, multicenter, open label, randomized phase III study to evaluate efficacy and safety of FFX versus CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years

NCT ID: NCT03412799 Completed - Clinical trials for Stage IV Pancreatic Cancer

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Start date: June 4, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.

NCT ID: NCT01652976 Completed - Clinical trials for Pancreatic Cancer Metastatic

Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma

FOLFOX-D
Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if the study drug, dasatinib, given in combination with 5-Fluorouracil, leucovorin and oxaliplatin (FOLFOX) will work against metastatic pancreatic cancer. Dasatinib is a Food and Drug Administration (FDA) approved drug for treating chronic myelogenous leukemia and acute lymphoblastic leukemia, however it is not currently approved for use in the treatment of pancreatic cancer.